MM-613 Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
- Resource Type
- Abstract
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S511-S512 - Subject
- Language
- ISSN
- 2152-2650